Quick Answer
Co-Diagnostics, Inc. reported R&D Expense of $19.14 million for fiscal year 2025.
Co-Diagnostics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $19.14M | -8.8% |
| 2024 | $20.98M | -8.6% |
| 2023 | $22.96M | +31.7% |
| 2022 | $17.44M | +16.5% |
| 2021 | $14.96M | +369.7% |
| 2020 | $3.19M | +132.3% |
| 2019 | $1.37M | +0.8% |
| 2018 | $1.36M | +35.7% |
| 2017 | $1.00M | +37.1% |
| 2016 | $731.5K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.48M | -8.2% | -4.4% |
| June 30, 2025 | $4.69M | -16.5% | -3.7% |
| March 31, 2025 | $4.87M | -14.3% | -0.2% |
| September 30, 2024 | $4.88M | -15.7% | -13.0% |
| June 30, 2024 | $5.61M | -6.2% | -1.2% |
| March 31, 2024 | $5.68M | +13.3% | -1.9% |
| September 30, 2023 | $5.79M | +14.9% | -3.2% |
| June 30, 2023 | $5.98M | +53.8% | +19.3% |
- Co-Diagnostics, Inc. showed a decrease of -8.8% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Co-Diagnostics, Inc.’s r&d expense has grown by 2516.3% (from $731.5 thousand to $19.14 million).
- The most recent figure is from Co-Diagnostics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: